The Transcription Factor Rfx3 Regulates β-Cell Differentiation, Function, and Glucokinase Expression by Ait-Lounis, Aouatef et al.
The Transcription Factor Rfx3 Regulates -Cell
Differentiation, Function, and Glucokinase Expression
Aouatef Ait-Lounis,
1 Claire Bonal,
2 Queralt Seguín-Este ´vez,
1 Christoph D. Schmid,
3 Philipp Bucher,
3
Pedro L. Herrera,
2 Be ´ne ´dicte Durand,
4 Paolo Meda,
5 and Walter Reith
1
OBJECTIVE—Pancreatic islets of perinatal mice lacking the
transcription factor Rfx3 exhibit a marked reduction in insulin-
producing -cells. The objective of this work was to unravel the
cellular and molecular mechanisms underlying this deﬁciency.
RESEARCH DESIGN AND METHODS—Immunoﬂuorescence
studies and quantitative RT-PCR experiments were used to study
the emergence of insulin-positive cells, the expression of tran-
scription factors implicated in the differentiation of -cells from
endocrine progenitors, and the expression of mature -cell
markers during development in Rfx3
/ and pancreas-speciﬁc
Rfx3-knockout mice. RNA interference experiments were per-
formed to document the consequences of downregulating Rfx3
expression in Min6 -cells. Quantitative chromatin immunopre-
cipitation (ChIP), ChIP sequencing, and bandshift experiments
were used to identify Rfx3 target genes.
RESULTS—Reduced development of insulin-positive cells in
Rfx3
/ mice was not due to deﬁciencies in endocrine progeni-
tors or -lineage speciﬁcation, but reﬂected the accumulation of
insulin-positive -cell precursors and defective -cells exhibiting
reduced insulin, Glut-2, and Gck expression. Similar incom-
pletely differentiated -cells developed in pancreas-speciﬁc Rfx3-
deﬁcient embryos. Defective -cells lacking Glut-2 and Gck
expression dominate in Rfx3-deﬁcent adults, leading to glucose
intolerance. Attenuated Glut-2 and glucokinase expression, and
impaired glucose-stimulated insulin secretion, were also induced
by RNA interference–mediated inhibition of Rfx3 expression in
Min6 cells. Finally, Rfx3 was found to bind in Min6 cells and
human islets to two well-known regulatory sequences, Pal-1 and
Pal-2, in the neuroendocrine promoter of the glucokinase gene.
CONCLUSIONS—Our results show that Rfx3 is required for the
differentiation and function of mature -cells and regulates the
-cell promoter of the glucokinase gene. Diabetes 59:1674–
1685, 2010
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ancreatic endocrine cells are organized into clus-
ters called islets of Langerhans. Mature mouse
islets contain a central core of insulin-producing
-cells surrounded by glucagon-producing -cells,
somatostatin-producing -cells, and pancreatic polypep-
tide (PP)-producing cells. During development, these en-
docrine cells arise in the primitive pancreatic epithelium
from progenitor cells expressing the transcription factor
Ngn3 (1). Ngn3 regulates speciﬁcation of the four endo-
crine cell lineages as a function of speciﬁc developmental
time windows (2). A complex network of transcription
factors directs the differentiation of Ngn3
 progenitors
into mature endocrine cells (3). Key factors implicated in
-cell development include NeuroD1, Nkx2.2, Pax4,
Nkx6.1, MafA, and Pdx1 (3). NeuroD1, encoded by an
Ngn3-regulated gene, is required for the formation of
-cells (4). Nkx2.2 functions downstream of NeuroD1 and
promotes commitment of cells to the , , and PP lineages
at the expense of the ε -cell lineage (5,6). A balance
between Arx and Pax4 expression controls speciﬁcation of
/ε versus / precursors (7). Nkx6.1 is expressed in cells
committed to the -lineage and participates in the devel-
opmental program leading to the generation of mature
-cells (8).
Mature -cells acquire the capacity to synthesize and
secrete insulin in response to variations in blood glucose
levels. Key components of the glucose-sensing and insulin
secretion machinery include the Glut-2 glucose trans-
porter and the glucose sensor glucokinase. Several tran-
scription factors have been implicated in the acquisition of
mature -cell functions, including Pdx1, MafA, and Neu-
roD1 (4,9,10).
There is growing evidence that Rfx transcription factors
are implicated in islet development. There are seven Rfx
factors (Rfx1–Rfx7) in mammals (11–13). With the excep-
tion of Rfx5, which is a well-known regulator in the
immune system (14), the functions of mammalian Rfx
factors have only started to emerge recently (15–19). Rfx6
was recently demonstrated to be crucial for islet develop-
ment in zebra ﬁsh, mice, and humans (18,19). We had
reported earlier that pancreatic Rfx3 expression is re-
stricted to islets and detected in Ngn3
 progenitors and ,
, , and PP cells (20). Islets of perinatal Rfx3
/ mice
contain reduced numbers of cells expressing insulin, glu-
cagon, and ghrelin, whereas PP-producing cells are in-
creased (20). Adult Rfx3
/ mice exhibit impaired glucose
tolerance (20). These ﬁndings suggested that Rfx3 is, like
Rfx6, implicated in the development of pancreatic endo-
crine cells, including -cells. However, the mechanisms
involved remained unknown.
We have performed a detailed analysis of -cell devel-
opment in Rfx3
/ mice and conditional pancreas-speciﬁc
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from E15.5 onward and characterized by the accumulation
of -cell precursors and defective -cells having reduced
insulin, Glut-2, and glucokinase expression. Impaired glu-
cose-stimulated insulin secretion and reductions in Glut-2
and glucokinase expression were induced in Min6 -cells
by RNA interference–mediated inhibition of Rfx3 expres-
sion. Finally, we identiﬁed the glucokinase gene as a direct
target of Rfx3. These results show that Rfx3 is required for
the differentiation and function of mature -cells, and that
it is a key regulator of glucokinase expression.
RESEARCH DESIGN AND METHODS
Mice. Data for Rfx3
/ mice, and mice carrying an Rfx3 allele in which exon
3 is ﬂanked by loxP sequences (Rfx3
loxP), have been reported (16). Pancreas-
speciﬁc Rfx3 deletion (Rfx3
P) was obtained by crossing mice carrying
Rfx3
loxP with Pdx1-Cre mice (21). Rfx3
P/ mice and Rfx3
loxP/ littermates
were obtained by mating Rfx3
loxP/ and Rfx3
/ /Pdx1-Cre mice. E0.5 was
deﬁned as the morning when a vaginal plug was detected. Genotyping was
done as described (16). Mice were on a C57BL/6 background. Experiments
were approved by the Federal and Cantonal veterinary authorities.
Staining of sections and morphometry. For E13.5 and E15.5, pancreases
were cut, respectively, into three or ﬁve consecutive series of 10 sections.
For E17.5 and E19.5, pancreases were cut into seven consecutive series of
10 sections. Measurements were performed using one section from each
series. Immunostaining of frozen sections was performed by standard proce-
dures. Antibodies and secondary reagents are indicated in supplementary
Table 1, available in the online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0986/DC1. Apoptotic cells were revealed by Tdt-
mediated dUTP nick end labeling (TUNEL) staining (Roche). Stained sections
were visualized by confocal microscopy. Cell counting and morphometry
were performed using Mertamorph v6.2 (Universal Imaging Corporation).
Labeled cells were quantiﬁed within Pdx1
 cells (E13.5 and E15.5) or
4,6-diamidino-2-phenylindole dihydrochloride (DAPI)-stained cells (E17.5
and E19.5).
Islet puriﬁcation. Mouse islets were isolated as described (22). Human islets
(purity 	90%, viability 	95%) were provided by the Islet Cell Resource Center
of Geneva (Juvenile Diabetes Research Foundation, European islet distribu-
tion program).
Quantitative RT-PCR. Total RNA was extracted from pancreas with RNeasy
kits (QIAGEN, Switzerland) and from Min6 cells and puriﬁed islets with
TRIzol (Invitrogen). Quantitative RT-PCR (qRT-PCR) was performed as de-
scribed (20). Results were normalized using TATA-binding protein (Tbp)
mRNA. Primers are provided in supplementary Table 2.
RNA interference. Double-stranded oligonucleotides encoding Rfx3-speciﬁc
and control (23) small interfering RNAs (siRNAs) were cloned into the
pLVTHM lentiviral vector (24). Five siRNA-encoding oligonucleotides were
tested for Rfx3. The best results were obtained with the following: 5-
CGCGTCCCCAACACTGGAGGAAATTACTTTCAAGAGAAGTAATTTCCTCC
AGTGTTTTTTTGGAAAT-3 (sense) and 5-CGATTTCCAAAAAAACACTGGA
GGAAATTACTTCTCTTGAAAGTAATTTCCTCCAGTGTTGGGGA-3 (antisense).
Min6 cells were transduced as described (24). GFP expression was used for
assessing transduction efﬁciencies and purifying transduced cells (FACS
Vantage Sorter, Becton Dickinson).
Glucose-stimulated insulin secretion. Glucose-stimulated insulin secre-
tion assays with Min6 cells were performed as described (25).
Rfx3 binding studies. ChIP was performed as described (26) using antibod-
ies speciﬁc for RFX3 (13). Primer sequences are provided in supplementary
Table 3. The ChIP-sequencing library was prepared from 10 ng of ChIP sample
(quantiﬁed by a Qubit ﬂuorometer; Invitrogen) using the ChIP-seq Sample
Preparation Kit (Illumina). Sequencing was performed with the Genome
Analyzer II (Illumina) using the 36 Cycle Sequencing Kit v2. Sequences
were derived from a single channel of the ﬂow cell. Data were processed using
the Illumina Pipeline Software package v1.0. Bandshift experiments were
performed as described (13) using in vitro translated Rfx3 and Min6 extracts.
Oligonucleotides used as probes and competitors are provided in supplemen-
tary Table 4.
Statistical analysis. Signiﬁcance was evaluated using a t test for indepen-
dent samples, one-way ANOVA followed by post-test comparisons, and
Kolmogorov-Smirnov or median nonparametric tests.
RESULTS
Impaired pancreatic endocrine-cell development in
Rfx3
/ embryos. Pancreas sections from E13.5, E15.5,
E17.5, and E19.5 embryos were stained with antibodies
against insulin (Fig. 1A). No differences in insulin-positive
cell numbers were observed between Rfx3
/ and wild-
type (WT) embryos at E13.5. A fourfold reduction in
insulin-positive cells was observed in Rfx3
/ embryos by
E15.5, and this reduction became accentuated at E17.5
(6-fold) and E19.5 (10-fold). A 10-fold decrease in insulin
(Ins) mRNA expression was revealed by qRT-PCR in the
pancreas of E15.5, E17.5, and E19.5 embryos (Fig. 1B).
Other islet defects described previously in perinatal
Rfx3
/ mice (20) also appeared early during development
(supplementary Figs. 1 and 2). Reductions in glucagon-
positive cells, and glucagon and ghrelin mRNA expression,
became evident by E15.5. Increases in PP
 cells and PP
mRNA levels were observed at E13.5. Somatostatin ex-
pression remained unchanged throughout development. In
agreement with the reduction in glucagon- and insulin-
positive cells, the number of cells expressing MafB—a
transcription factor implicated in - and -cell develop-
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FIG. 1. Development of insulin-positive cells is severely impaired in
Rfx3
/ embryos. A: Pancreas sections from WT (/) and Rfx3
/
(/) embryos at stages E13.5, E15.5, E17.5, and E19.5 were stained
with antibodies against insulin. Nuclei were labeled with DAPI. Repre-
sentative sections are shown (top). The percentages of insulin-positive
cells were quantiﬁed in total Pdx1
 cells (E13.5 and E15.5) or in the
entire pancreas (E17.5 and E19.5) of WT (/) and Rfx3
/ (/)
embryos (bottom). B: Ins2 mRNA abundance was measured by qRT-
PCR in total pancreas RNA from WT (/) and Rfx3
/ (/) embryos
at stages E15.5, E17.5, and E19.5. The results were normalized using
Tbp mRNA and are expressed relative to the levels found in WT
embryos. The mean  SEM derived from ﬁve embryos is shown for each
stage and genotype; ***P < 0.0001; **P < 0.001; *P < 0.05. (A
high-quality color representation of this ﬁgure is available in the
online issue.)
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throughout development (supplementary Fig. 3).
Early pancreatic development is normal in Rfx3
/
embryos. To determine whether the reduction in insulin-
positive cells in Rfx3
/ embryos might be secondary to a
global defect in pancreas formation, we examined the
pancreas at critical developmental stages. Pancreatic tis-
sue in Rfx3
/ embryos was normal in size and gross
morphology at E12.5, E15.5, and E19.5 (supplementary
Fig. 4).
We next quantiﬁed the expression of transcription fac-
tors playing pivotal roles in multipotent pancreatic-pro-
genitor cells (Pdx1 and Ptf1a), developing exocrine cells
(Ptf1a), and endocrine-progenitor cells (Ngn3) (supple-
mentary Figs. 5 and 6) (3). At E13.5, the developing
pancreas of Rfx3
/ embryos appeared well branched and
contained WT numbers of Pdx1
 cells. The pancreas of
E13.5 and E15.5 Rfx3
/ embryos also contained WT
numbers of Ptf1a
 cells concentrated in growing acini.
qRT-PCR experiments conﬁrmed that Ptf1a mRNA levels
were unaffected throughout development. Finally, the
number of cells expressing Ngn3 was not altered in
Rfx3
/ embryos at E13.5, E15.5, or E19.5. qRT-PCR
experiments conﬁrmed that Ngn3 mRNA was expressed at
WT levels at all stages in Rfx3
/ embryos. The deﬁciency
in Rfx3 does thus not affect early morphogenesis of
the pancreatic epithelium, impair development of the
exocrine pancreas, or lead to altered numbers of Ngn3

progenitors.
Normal -lineage speciﬁcation in Rfx3
/ embryos.
As the deﬁciency in insulin-positive cells and reduced Ins2
mRNA expression ﬁrst became evident in Rfx3
/ em-
bryos at E15.5, this stage was examined for the expression
of transcription factors implicated in -cell development
(Fig. 2A–D). Cells expressing Pdx1, Pax4, and Nkx6.1 were
not reduced in E15.5 Rfx3
/ embryos. No signiﬁcant
decreases in Pdx1, Pax4, Nkx6.1, Nkx2.2,o rNeurod1
mRNAs were observed at E15.5. These ﬁndings suggest
that the emergence of cells committed to the -lineage is
not affected in Rfx3
/ embryos.
The frequencies of apoptotic or proliferating cells were
not affected in the islets of E15.5 Rfx3
/ embryos (Fig.
2E). Altered islet development is therefore not due to
increased apoptosis or decreased proliferation.
Defective -cell differentiation in Rfx3
/ mice. To
clarify the phenotype of the -lineage cells that develop in
Rfx3
/ embryos, we examined later developmental
stages for the expression of transcription factors required
for -cell differentiation and function. Nkx2.2, Nkx6.1,
Neurod1, and Mafa mRNA levels were not reduced in the
pancreas of Rfx3
/ embryos at E17.5 and E19.5 (Fig. 3A).
Pdx1 mRNA expression was reduced modestly at E19.5
but not affected at E17.5 (Fig. 3A). Nkx6.1
 and Pdx1
 cell
numbers were indistinguishable between WT and Rfx3
/
embryos (Fig. 3B–C).
We next analyzed the differentiation status of Nkx6.1

and Pdx1
 -lineage cells in WT and Rfx3
/ embryos
at E17.5 and E19.5 (Fig. 3B and C). These markers
become restricted to -cells as pancreas development
progresses (8,27). The fractions of Nkx6.1
 cells that
express or lack insulin were quantiﬁed independently at
E17.5 and E19.5. In WT embryos, Nkx6.1
insulin
 cells
increased from 44% at E17.5 to 68% at E19.5. Conversely,
Nkx6.1
 insulin
 cells decreased from 56% at E17.5 to
42% at E19.5. In Rfx3
/ embryos, Nkx6.1
insulin
 cells
attained only 22% at E19.5, whereas Nkx6.1
insulin

cells constituted the major -cell fraction (78–88%).
Similar results were obtained by quantifying Pdx1
insulin
and
Pdx1
insulin
 cells at E19.5. Whereas Pdx1
insulin
 cells
constituted the major fraction (80%) in WT embryos,
Pdx1
insulin
 cells predominated (78%) in Rfx3
/
embryos.
A signiﬁcant fraction of Nkx6.1
 cells in Rfx3
/ em-
bryos exhibited ectopic PP expression (supplementary
Fig. 7A). These Nkx6.1
PP
 cells do not co-express
insulin (supplementary Fig. 7B). Lineage-tracing experi-
ments have suggested that -cells develop from precursors
expressing PP (28). The increase in PP
 cells in Rfx3-
deﬁcient mice might thus reﬂect the persistence of PP-
expressing -cell precursors.
Defective -cell differentiation in pancreas-speciﬁc
Rfx3-knockout mice. Rfx3 is required for the formation
of cilia on the embryonic node, which direct the estab-
lishment of left-right asymmetry (29). Most Rfx3
/
mice therefore die from developmental defects involv-
ing abnormal speciﬁcation of the left-right body axis
(16). We could consequently not exclude that the pan-
creatic phenotype observed in Rfx3
/ embryos might
be an indirect consequence of body-patterning abnor-
malities. We therefore generated pancreas-speciﬁc Rfx3
knockout mice. Mice carrying an Rfx3 allele containing
an essential exon ﬂanked by loxP sequences (Rfx3
loxP)
were crossed with transgenic mice expressing Cre re-
combinase under control of the Pdx1 promoter (Pdx1-
Cre) (Fig. 4A). Rfx3
loxP//Pdx1-Cre mice carrying a
pancreas-speciﬁc Rfx3 deletion (Rfx3
P/ mice) were
born according to expected Mendelian frequencies and
did not exhibit any overt developmental anomalies.
Immunoﬂuorescence staining of pancreas sections from
E19.5 embryos demonstrated that the number of Rfx3

nuclei was reduced over ﬁvefold in the islets of Rfx3
P/
mice (Fig. 4B).
Insulin-positive islet cells were reduced threefold in
E19.5 Rfx3
P/ embryos compared with Rfx3
loxP/ con-
trols (Fig. 4C). As in Rfx3
/ mice (24), the -cell defect in
Rfx3
P/ mice leads to impaired glucose tolerance in
adults (Fig. 4D). Furthermore, the islets of E19.5 Rfx3
P/
embryos contained fewer glucagon-positive cells and in-
creased numbers of PP
 cells (supplementary Fig. 8).
Finally, cilia in the islets were shorter and reduced in
number (supplementary Fig. 9). These results conﬁrmed
that all of the islet cell defects documented in Rfx3
/
mice result from a pancreas-intrinsic deﬁciency in Rfx3.
We next quantiﬁed Nkx6.1
, Nkx6.1
insulin
, and
Nkx6.1
insulin
 cells in pancreatic sections from
Rfx3
P/ and Rfx3
loxP/ embryos at E19.5 (Fig. 4E). As in
Rfx3
/ mice, the pancreas of Rfx3
P/ embryos con-
tained WT numbers of total Nkx6.1 cells, a marked reduc-
tion in Nkx6.1
insulin
 cells, and a corresponding
increase in Nkx6.1
insulin
 cells (Fig. 4E).
Rfx3
/ mice exhibit a block in -cell maturation. The
accumulation of Nkx6.1
insulin
 and Pdx1
insulin
 cells
in Rfx3-deﬁcient islets suggested that there is a develop-
mental block in the -cell lineage. We therefore examined
the expression of key mature -cell markers in Rfx3
/
(Fig. 5) and Rfx3
P/ (supplementary Fig. 10A) embryos.
Glut-2 (Slc2a2) and glucokinase (Gck) mRNA levels were
signiﬁcantly reduced in E17.5 and E19.5 Rfx3
/ embryos,
whereas there was no reduction in PC1/3 (Pcsk1) mRNA.
There was a marked reduction in cells exhibiting strong
Glut-2 and glucokinase expression in the islets of E19.5
Rfx3
/ and Rfx3
P/ embryos. The residual insulin-posi-
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staining. No change in the number of PC1/3
 cells was
evident. These ﬁndings conﬁrmed that the deﬁciency in
Rfx3 leads to the accumulation of cells characterized by
normal expression of certain -cell markers (Nkx6.1,
Pdx1, PC1/3) but impaired expression of key proteins
required for -cell function (Glut-2, glucokinase, insulin).
Insulin-positive cell numbers were not reduced mark-
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FIG. 2. The expression of key transcription factors implicated in -cell development is normal in Rfx3
/ embryos. A: Pancreas sections from WT
(/) and Rfx3
/ (/) embryos at stage E15.5 were stained with DAPI and antibodies against Pdx1. Representative sections are shown (left).
Pdx1
 cells and Pdx1 mRNA levels were quantiﬁed in the pancreases of WT (/) and Rfx3
/ (/) embryos (right). B: Pancreas sections from
WT (/) and Rfx3
/ (/) embryos at stage E15.5 were stained with DAPI and antibodies against Pax4. Representative sections are shown
(left). Pax4
 cells and Pax4 mRNA levels were quantiﬁed in the pancreases of WT (/) and Rfx3
/ (/) embryos (right). Pax4
 cells were
expressed as percentage of Pdx1
 cells (counted on serial sections). C: Pancreas sections from WT (/) and Rfx3
/ (/) embryos at stage
E15.5 were stained with DAPI and antibodies against Nkx6.1. Representative sections are shown (left). Nkx6.1
 cells and Nkx6.1 mRNA levels
were quantiﬁed in the pancreases of WT (/) and Rfx3
/ (/) embryos (right). Nkx6.1
 cells were expressed as percentage of Pdx1
 cells
(counted on serial sections). D: Nkx2.2 and Neurod1 mRNA levels were quantiﬁed in total pancreas RNA from WT (/) and Rfx3
/ (/) embryos
at stage E15.5. The results were normalized using Tbp mRNA and are expressed relative to the levels found in WT embryos. The mean  SEM derived
from ﬁve embryos is shown for each stage and genotype. ns, not signiﬁcant. E: TUNEL staining and labeling with anti–phospho-histone H3 antibodies
were used to quantify the percentages of apoptotic and proliferating islet cells in pancreatic sections from E15.5 Rfx3
/ and Rfx3
/ embryos. Means
are shown for four embryos of each genotype. (A high-quality color representation of this ﬁgure is available in the online issue.)
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P/ or Rfx3
/ adults, indicating that the
-cell mass is restored in postnatal mice (supplementary
Fig. 10B). These adult -cells remain defective with re-
spect to Glut-2 and glucokinase expression (supplemen-
tary Fig. 10B). This defect is associated with impaired
glucose tolerance in Rfx3
P/ (Fig. 4D) and Rfx3
/ (20)
mice.
Rfx3 is required for mature -cell function. To docu-
ment a potential role of Rfx3 in mature -cells, we
inhibited Rfx3 expression by RNA interference in the Min6
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ﬁgure is available in the online issue.)
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those observed in mouse islets (supplementary Fig. 11A).
Min6 cells were transduced with lentiviral vectors encod-
ing Rfx3-speciﬁc or control siRNAs. Signiﬁcant (albeit
partial) reductions in Rfx3 protein and mRNA were in-
duced in cells expressing the Rfx3 siRNA (Fig. 6A, supple-
mentary Fig. 11B).
The impact of inhibiting Rfx3 expression on insulin
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(/) embryos at stage E19.5 were stained with antibodies against insulin and Glut-2 (A), glucokinase (B), or PC1/3 (C). Representative sections
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/ embryos show only weak Glut-2 and glucokinase expression (arrows). Slc2a2 (A), Gck
(B), and Pcsk1 (C) mRNA levels were quantiﬁed in the pancreases of WT (/) and Rfx3
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proaches: quantifying insulin-staining intensity of individ-
ual cells by confocal microscopy, measurement of total
insulin content by acid-ethanol extraction, and quantiﬁca-
tion of Ins2 mRNA. Although there were modest reduc-
tions in insulin staining and Ins2 mRNA in cells
expressing the Rfx3 siRNA (Fig. 6B and C, supplementary
Fig. 11B), this was not paralleled by a signiﬁcant decrease
in total insulin content (data not shown). Slc2a2 and Gck
mRNAs were signiﬁcantly decreased in cells expressing
the Rfx3 siRNA (Fig. 6C). The reductions in Slc2a2 and
Gck mRNAs were similar to that observed for a gene
(Dync2li1) known to be regulated by Rfx3 (Fig. 6C)
(16,20). In contrast, as observed in Rfx3
/ embryos, there
was no decrease in Nkx6.1, Nkx2.2, and Pcsk1 mRNAs
(Fig. 6C).
To test the effect of inhibiting Rfx3 expression on the
secretory function of the transduced Min6 cells, we exam-
ined their insulin secretion in response to glucose or
glucose plus agents raising cAMP (IBMX and forskolin)
(Fig. 6D). The inhibition of Rfx3 expression did not affect
insulin content (data not shown), but led to signiﬁcantly
elevated basal insulin release. As a result, stimulatory
levels of glucose were unable to increase insulin output, as
was observed in cells transduced with an empty vector or
a vector encoding an irrelevant siRNA. This change was
not due to the transduction protocol, since normal basal
and glucose-stimulated insulin secretion was observed
with the two control cell types. It could also not be
ascribed to nonspeciﬁc inhibition of the secretory machin-
ery, since stimulation with glucose in the presence of
isomethyl butyl xanthine (IBMX) plus forskolin increased
insulin release similarly in the three types of Min6 cells
(Fig. 6D).
The -cell promoter of the Gck gene is regulated by
Rfx3. To determine if the Ins2, Gck,o rSlc2a2 genes might
be direct targets of Rfx3, we analyzed the results of a
chromatin immunoprecipitation sequencing (ChIP-seq) ex-
periment performed with Rfx3-speciﬁc antibodies and
chromatin from Min6 cells. Two peaks were observed in
the promoter that drives Gck expression in -cells (Fig.
7A). This double peak coincided with two highly con-
served sequences showing homology to the consensus Rfx
binding site (30). Binding of Rfx3 to the Gck promoter was
as evident as at the control Dync2li1 promoter. No signals
were observed at the liver-speciﬁc Gck promoter, the Ins2
and Slc2a2 genes, or genes that are not expected to be
targets of Rfx3 on the basis of our siRNA experiments and
the analysis of Rfx3
/ mice (Fig. 7A, supplementary Fig.
12, data not shown).
Quantitative ChIP (qChIP) experiments conﬁrmed that
Rfx3 binds to the Gck promoter in Min6 cells, albeit not as
strongly as at the Dync2li1 promoter (Fig. 7B). Binding of
Rfx3 was not observed at the Slc2a2 or Ins2 genes. qChIP
experiments performed with puriﬁed human islets demon-
strated that RFX3 also binds to the human GCK promoter
(Fig. 7B).
The Rfx3 binding motifs in the Gck promoter lie within
a region that is essential and sufﬁcient for driving -cell
expression in vitro and in vivo (Fig. 7C) (31–34). They
correspond to two palindromic sequences (Pal-1 and
Pal-2) known to be critical for activation of the Gck
promoter in -cells (34,35). That Rfx3 can bind speciﬁcally
to the Pal-1 and Pal-2 motifs was conﬁrmed by bandshift
experiments performed with recombinant Rfx3 and Min6
extracts (Fig. 7D, supplementary Fig. 13). These ﬁndings
C  control   siRfx3 
m
R
N
A
 
Slc2a2 
Nkx2.2 
Nkx6.1 
Dync2li1
Pcsk1
Rfx3
Ins2
Gck  
0 
0.2 
0.4 
0.6 
0.8 
1.0 
* 
*  *  *  * 
s
i
R
f
x
3
 
A Rfx3  GFP 
c
o
n
t
r
o
l
 
merged 
R
f
x
3
 
i
n
t
e
n
s
i
t
y
 
/
 
c
e
l
l
 
a
r
e
a
 
0 
10 
20 
30 
40 
50 
 * 
c
o
n
t
r
o
l
 
s
i
R
f
x
3
 
1
8
0
 
3
9
0
 
B
C
o
n
t
r
o
l
 
s
i
R
f
x
3
 
Insulin  GFP  merged 
I
n
s
u
l
i
n
 
i
n
t
e
n
s
i
t
y
 
/
 
c
e
l
l
 
a
r
e
a
 
 
c
o
n
t
r
o
l
 
s
i
R
f
x
3
  0 
10 
20 
30 
40 
 * 
1
8
0
 
3
9
0
 
0 
0.5 
1.0 
1.5 
2.0 
2.5 
10 
20 
control vector  siRfx3 
i
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
 
(
%
 
c
o
n
t
e
n
t
)
  D 
1.4 mM glucose 
4.2 mM glucose 
8.4 mM glucose 
16.8 mM glucose 
16.8 mM glucose 
+  0.1 mM IBMX 
 + 1 µM FSK 
3  12  3 
3 
3 
3 
9 
12 
12 
9 
12  9 
12 12 
9 
* ** 
FIG. 6. Rfx3 is required for maintaining -cell maturity. Min6 cells were
transduced with lentiviral vectors expressing control or Rfx3-speciﬁc
siRNAs (siRfx3). The vectors also express GFP. A: Transduced cells were
stained with antibodies against Rfx3 and examined by ﬂuorescence
microscopy to visualize Rfx3 (red) and GFP (green) expression. Repre-
sentative ﬁelds are shown (left). The bar graph (right) shows the quan-
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ined by ﬂuorescence microscopy to visualize insulin (red) and GFP
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thine. (A high-quality digital representation of this ﬁgure is available in the
online issue.)
A. AIT-LOUNIS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1681FIG. 7. Rfx3 binds to two key regulatory elements in the -cell–speciﬁc promoter of the Gck gene. A: The proﬁles show the number of ChIP-seq
reads mapping to the upstream regions of the Dync2li1, Gck, Slc2a2, and Ins2 genes. Transcription start sites (arrows), transcribed regions
(open boxes), and scales in base pairs (bp) are indicated. Peaks corresponding to binding of Rfx3 were observed in the promoters of the Dync2li1
and Gck genes. The positions of these peaks coincide with conserved Rfx binding motifs (black boxes). The motifs found in the promoters of the
mouse, rat, and human Dync2li1 and Gck genes are shown aligned with the consensus Rfx-binding site. No binding of Rfx3 was observed at the
promoters of the Ins2 or Slc2a2 genes. B: Binding of Rfx3 to the promoters of the Dync2li1, Gck, Slc2a2, and Ins2 genes was assessed by
quantitative ChIP in Min6 cells (left) or puriﬁed human islets (right). Control regions were included as background (backgr.) references. Results
are expressed relative to binding of Rfx3 at the Dync2li1 promoter and show the mean  SEM derived from three independent experiments. C:
Schematic map of the Gck gene. Transcription of the Gck gene is regulated by two alternative cell type–speciﬁc promoters. The ﬁrst promoter
drives Gck expression in -cells. The second promoter, situated 35 kb further downstream, is used in the liver. The two Rfx3 binding sites
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DISCUSSION
Strongly decreased numbers of insulin-positive cells be-
came evident in Rfx3
/ embryos by E15.5 and persisted
until birth. This could not be attributed to a deﬁciency in
Ngn3
 progenitors, altered islet cell apoptosis or prolifer-
ation, or defective -lineage speciﬁcation. Instead, -lin-
eage cells develop in Rfx3
/ embryos, but remain
incompletely differentiated. Few, if any, of these cells have
a mature -cell phenotype. A minority (20%) correspond
to insulin-positive -cells exhibiting defective glucokinase
and Glut-2 expression. The majority (80%) have a phe-
notype that could correspond to late -cell precursors
(Ngn3
, NKx6.1
, Pdx1
, insulin
, glucokinase
, Glut-
2
). The latter are not simply endocrine progenitors since
they lack Ngn3 expression (3,21). A similar skewed distri-
bution of -lineage cells is observed in pancreas-speciﬁc
Rfx3-knockout embryos, indicating that it results from an
endocrine cell–intrinsic deﬁciency in Rfx3. Defective
-cells lacking glucokinase and Glut-2 expression persist
in adult Rfx3
/ and conditional Rfx3-deﬁcient mice,
leading to intolerance to glucose. Downregulating Rfx3
expression in Min6 cells provoked reduced Glut-2 and
glucokinase expression and an elevation of basal insulin
release, which prevented the detection of a glucose-
stimulated increase in insulin output. Collectively, these
ﬁndings indicate that Rfx3 is critical for both -cell differ-
entiation and the function of mature -cells.
The Gck gene is regulated by two cell type–speciﬁc
promoters (36). The most upstream promoter drives ex-
pression in -cells and various other cell types, including
glucose-sensitive neurons in the central nervous system
and endocrine cells in the gut and pituitary gland
(31,37,38). This neuroendocrine promoter is essential and
sufﬁcient for driving glucokinase expression in -cells in
vitro and in vivo (31–34). Rfx3 binds to two sequences in
the neuroendocrine promoter in Min6 cells. RFX3 also
binds to this promoter in human islets. The Rfx3 binding
sites correspond to two palindromic sequences (Pal-1 and
Pal-2) that are essential for regulating -cell activity of
the neuroendocrine promoter in rodents and humans
(34,35,39). Gel-retardation, footprint, methylation-interfer-
ence, and cross-linking experiments have demonstrated
that Pal-1 and Pal-2 are recognized by nuclear factors in
-cells (33–35,39). Until now, the identity of these factors
remained unknown. Our results show that the function of
Pal-1 and Pal-2 is mediated by binding of Rfx3. Rfx3 thus
collaborates with other -cell–speciﬁc transcription fac-
tors, such as Pdx1 and NeuroD1 (36,40,41), in regulating
Gck expression in -cells.
Mice heterozygous for a deletion of the neuroendo-
crine promoter (which present only a 50% reduction in
glucokinase expression in islets) exhibit hyperglycemia,
intolerance to glucose, reduced glucose-stimulated hyper-
insulinemia, and impaired glucose-stimulated insulin se-
cretion (42). Similarly, mice heterozygous for a pancreas-
speciﬁc Gck deletion exhibit an impaired ability to raise
plasma insulin concentrations in response to glucose (43).
A modest decrease in Gck expression is thus sufﬁcient for
perturbing glucose-stimulated insulin secretion and the
maintenance of glucose homeostasis. Attenuated glucoki-
nase expression in -cells can thus explain, at least in part,
why Rfx3
/ and Rfx3
P/ mice are intolerant to glucose.
Loss-of-function mutations in the human GCK gene
cause one form of maturity-onset diabetes of the young
(MODY-2) and permanent neonatal diabetes (44). A muta-
tion in the neuroendocrine GCK promoter was recently
found to be responsible for reduced glucokinase expres-
sion in certain MODY patients (45). Interestingly, this
mutation lies immediately adjacent to the Pal-1 motif.
Other forms of MODY result from mutations in genes
encoding transcription factors that regulate the expression
of GCK and/or play other key roles in -cell function (45).
Because we have identiﬁed Rfx3 as a critical regulator of
Gck expression and mature -cell function, it is tempting
to speculate that mutations within the RFX3 gene, or in its
regulatory regions, could give rise to MODY or other
diseases characterized by pancreas dysfunction, defective
insulin secretion, and/or perturbed glucose homeostasis.
We have as yet not elucidated the mechanisms respon-
sible for reduced insulin and Glut-2 expression in -lineage
cells of Rfx3
/ mice. Neither gene is a direct target of
Rfx3. Binding of Rfx3 was also not observed at the genes
encoding NeuroD1, Pdx1, or MafA, which are known to
activate insulin gene transcription (46), and the expression
of these transcription factors was not affected in Rfx3
/
mice. Furthermore, analysis of our ChIP-seq data has not
revealed other target genes known to be implicated in
insulin or Glut-2 expression. Finally, the deﬁciencies in
insulin-positive cells and insulin expression in Rfx3
/
mice are unlikely to be indirect consequences of reduced
glucokinase expression, because no reductions in -cell
mass or pancreatic insulin content were documented in
Gck-deﬁcient mice (42).
Our ChIP-seq data have indicated that Rfx3 binds to the
promoters of hundreds of genes implicated in the forma-
tion and function of cilia (data not shown). This is
consistent with the fact that Rfx3 is required for the
biogenesis of cilia on various cell types, including pancre-
atic endocrine cells (20,47). However, the functions of cilia
in islets are unknown. No defects were observed in mice in
which cilia were ablated in the pancreas by deletion of the
Kif3a gene (47). It therefore remains to be determined
whether the ciliary defects in Rfx3
/ mice contribute
directly or indirectly to perturbed islet cell development
and/or function.
The islet defects in Rfx3-deﬁcient mice are strikingly
similar, albeit not identical, to those observed in Rfx6-
deﬁcient mice (18). Shared features include impaired
development of mature endocrine cells expressing insu-
lin, glucagon, and ghrelin; increased numbers of cells
expressing PP; normal expression of transcription fac-
tors implicated in -cell speciﬁcation (Nkx6-1, Nkx2-2);
the accumulation of Nkx6.1
 cells lacking insulin; the
correspond to the previously identiﬁed Pal-1 and Pal-2 sequences centered on nucleotides 159 and 81 of the -cell promoter. The approximate
positions of other known regulatory elements (E-box, UPE-1, UPE-2, UPE-3) and binding sites for transcription factors (Beta2/NeuroD1, Pdx1)
implicated in Gck expression in -cells are indicated. The map of the Gck promoter is based on the study by Im et al. (36). D: Bandshift
experiments were performed with recombinant Rfx3 (left gels) and Min6 extracts (right gels) using double-stranded oligonucleotide probes
containing Pal-1, Pal-2, and a known Rfx binding site (Py) from the polyoma-virus enhancer. The regions of the gels containing the major band
corresponding to binding of Rfx3 are shown (see supplementary Fig. 11). Binding reactions were supplemented as indicated below with unlabeled
competitor oligonucleotides containing the Py, Pal-1, mutated Pal-1 (Pal-1m), Pal-2, or mutated Pal-2 (Pal-2m) sites. The corresponding
sequences are shown aligned with the consensus Rfx binding site. Mutated nucleotides are underlined and in lower case.
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 cells expressing PP; and re-
duced Glut-2 and Gck expression. Notable differences
include the development of cells expressing somatosta-
tin, which is defective in Rfx6
/ mice but normal in
Rfx3-deﬁcient mice, and the development of cilia on
islet cells, which is impaired in Rfx3-deﬁcent mice but
unaffected in Rfx6
/ mice. A likely explanation for the
partially overlapping phenotype is that Rfx3 and Rfx6
collaborate to regulate a common set of genes by
binding as Rfx3-Rfx6 heterodimers and distinct sets of
genes by binding as either Rfx3 and Rfx6 homodimers,
or heterodimers with other Rfx factors. One common
target gene is likely to be Gck, since preliminary ChIP
experiments have suggested that its -cell promoter is
bound by both Rfx3 and Rfx6.
Detailed understanding of the programs governing -cell
differentiation is a prerequisite for the development of
-cell replacement therapies for diabetes relying on
-cells generated by guided differentiation of stem or
progenitor cells, or trans-differentiation of other mature
cells (3,48,49). Although major progress has been made,
successful generation of mature -cells has so far been
mitigated because the program controlling -cell differen-
tiation is only partially understood. Our results contribute
signiﬁcantly to elucidation of this program and may there-
fore be valuable for the generation of functional -cells in
vitro.
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